This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Immuno-oncology therapies are close to delivering on their promise, but still face significant obstacles in terms of expansion to other indications, pricing challenges, and regulatory strategy. Eva Marchese and Cécile Matthews discuss these challenges in their article in The Pharma Letter.
Click here to read the article or download a copy.
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Digital therapeutics (DTx) leverage technology to deliver evidence-based treatments for various health conditions, aiming to complement or replace traditional...
